These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 23617831)
1. T cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patients. Tüting T Pigment Cell Melanoma Res; 2013 Jul; 26(4):441-56. PubMed ID: 23617831 [TBL] [Abstract][Full Text] [Related]
2. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies. Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962 [TBL] [Abstract][Full Text] [Related]
3. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. Grover A; Kim GJ; Lizée G; Tschoi M; Wang G; Wunderlich JR; Rosenberg SA; Hwang ST; Hwu P Clin Cancer Res; 2006 Oct; 12(19):5801-8. PubMed ID: 17020987 [TBL] [Abstract][Full Text] [Related]
4. Update on vaccines for high-risk melanoma. Weiss SA; Chandra S; Pavlick AC Curr Treat Options Oncol; 2014 Jun; 15(2):269-80. PubMed ID: 24788575 [TBL] [Abstract][Full Text] [Related]
5. Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma. Dillman RO; Cornforth AN; Depriest C; McClay EF; Amatruda TT; de Leon C; Ellis RE; Mayorga C; Carbonell D; Cubellis JM J Immunother; 2012 Oct; 35(8):641-9. PubMed ID: 22996370 [TBL] [Abstract][Full Text] [Related]
6. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810 [TBL] [Abstract][Full Text] [Related]
7. Advances in Immunotherapy for Melanoma: A Comprehensive Review. Rodríguez-Cerdeira C; Carnero Gregorio M; López-Barcenas A; Sánchez-Blanco E; Sánchez-Blanco B; Fabbrocini G; Bardhi B; Sinani A; Guzman RA Mediators Inflamm; 2017; 2017():3264217. PubMed ID: 28848246 [TBL] [Abstract][Full Text] [Related]
9. Multiple antigen-targeted immunotherapy with alpha-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells. Fukushima S; Hirata S; Motomura Y; Fukuma D; Matsunaga Y; Ikuta Y; Ikeda T; Kageshita T; Ihn H; Nishimura Y; Senju S J Immunother; 2009 Apr; 32(3):219-31. PubMed ID: 19242378 [TBL] [Abstract][Full Text] [Related]
10. Translational research in melanoma. Tsai S; Sabel MS Surg Oncol Clin N Am; 2008 Apr; 17(2):391-419, ix-x. PubMed ID: 18375359 [TBL] [Abstract][Full Text] [Related]
11. Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine. Block MS; Suman VJ; Nevala WK; Kottschade LA; Creagan ET; Kaur JS; Quevedo JF; McWilliams RR; Markovic SN Melanoma Res; 2011 Oct; 21(5):438-45. PubMed ID: 21697748 [TBL] [Abstract][Full Text] [Related]
12. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma. Aravindaram K; Wang PH; Yin SY; Yang NS Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790 [TBL] [Abstract][Full Text] [Related]
13. T-cell-based immunotherapy of melanoma: what have we learned and how can we improve? Campoli M; Ferrone S Expert Rev Vaccines; 2004 Apr; 3(2):171-87. PubMed ID: 15056043 [TBL] [Abstract][Full Text] [Related]
14. Phase I/IB study of immunization with autologous tumor cells transfected with the GM-CSF gene by particle-mediated transfer in patients with melanoma or sarcoma. Mahvi DM; Sondel PM; Yang NS; Albertini MR; Schiller JH; Hank J; Heiner J; Gan J; Swain W; Logrono R Hum Gene Ther; 1997 May; 8(7):875-91. PubMed ID: 9143914 [TBL] [Abstract][Full Text] [Related]
15. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. Panelli MC; Wunderlich J; Jeffries J; Wang E; Mixon A; Rosenberg SA; Marincola FM J Immunother; 2000; 23(4):487-98. PubMed ID: 10916759 [TBL] [Abstract][Full Text] [Related]